oncotomskСибирский онкологический журналSiberian journal of oncology1814-48612312-3168Tomsk National Research Medical Сепtеr of the Russian Academy of Sciences10.21294/1814-4861-2016-15-4-45-49oncotomsk-384Research ArticleКЛИНИЧЕСКИЕ ИССЛЕДОВАНИЯCLINICAL STUDIESНЕОАДЪЮВАНТНАЯ ПОЛИХИМИОТЕРАПИЯ С РАДИКАЛЬНОЙ ЦИСТЭКТОМИЕЙ В ЛЕЧЕНИИ МЫШЕЧНО-ИНВАЗИВНОГО РАКА МОЧЕВОГО ПУЗЫРЯNEOADJUVANT CHEMOTHERAPY WITH RADICAL CYSTECTOMY IN THE TREATMENT OF MUSCLE-INVASIVE BLADDER CANCERНургалиевН. С.NurgalievN. S.

Нургалиев Нуржан Серикович, кандидат медицинских наук, руководитель центра онкоурологии 

SPIN-код: 6171-7346

Nurglaliev Nurzhan S., MD, PhD, Head of Oncourological Center 

. SPIN-code: 6171-7346

nurgaliyev.ns@gmail.comАрзыкуловЖ. А.ArzykulovZh. A.ИшкининЕ. И.ShkininE. I.Казахский НИИ онкологии и радиологии, АлматыКазахстанKazakh Oncology and Radiology Research Institute, AlmatyKazakhstan2016281020161544549Copyright © Нургалиев Н.С., Арзыкулов Ж.А., Ишкинин Е.И., 20162016Нургалиев Н.С., Арзыкулов Ж.А., Ишкинин Е.И.Nurgaliev N.S., Arzykulov Z.A., shkinin E.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.siboncoj.ru/jour/article/view/384

Представлены результаты комбинированного лечения 36 больных мышечно-инвазивным раком мочевого пузыря, получавших неоадъювантную полихимиотерапию (НАПХТ) по схеме гемзар + цисплатин. В контрольную группу включено 167 больных, которым проводилось хирургическое лечение. При многофакторном статистическом анализе установлено, что применение НАПХТ значимо улучшает отдаленные результаты лечения при умеренной степени дифференцировки опухоли (G2), при РМП II стадии, при отсутствии поражения лимфоузлов (N0) и у пациентов моложе 65 лет.

The results of the combined treatment of 36 patients with muscle-invasive bladder cancer treated with neoadjuvant combination chemotherapy with Gemzar + Cisplatin. The control group included 167 patients who underwent surgical treatment. In multivariate statistical analysis found that the use neoadjuvant combination chemotherapy significantly improves long-term results of treatment at a moderate degree of tumor differentiation (G2), bladder cancer II stage, in the absence of lymph node involvement (N0) and in patients younger than 65 years. 

рак мочевого пузырянеоадъювантная химиотерапиявыживаемостьbladder cancerneoadjuvant combination chemotherapysurvivalReferencesFerlay J., Soerjomataram I., Ervik M., Dikshit R., Eser S., Mathers C., Rebelo M., Parkin D.M., Forman D., Bray F. GLOBOCAN 2012 v1.1, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2014. Available from: http://globocan.iarc.fr, accessed on 08/09/2015.Ferlay J., Soerjomataram I., Ervik M., Dikshit R., Eser S., Mathers C., Rebelo M., Parkin D.M., Forman D., Bray F. GLOBOCAN 2012 v1.1, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2014. Available from: http://globocan.iarc.fr, accessed on 08/09/2015.Apolo A.B., Kim J.W., Bochner B.H., Steinberg S.M., Bajorin D.F., Kelly W.K., Agarwal P.K., Koppie T.M., Kaag M.G., Quinn D.I., Vogelzang N.J., Sridhar S.S. Examining the management of muscle-invasive bladder cancer by medical oncologists in the United States. Urol Oncol. 2014 Jul; 32 (5): 637–44. doi: 10.1016/j.urolonc.2013.12.012.Apolo A.B., Kim J.W., Bochner B.H., Steinberg S.M., Bajorin D.F., Kelly W.K., Agarwal P.K., Koppie T.M., Kaag M.G., Quinn D.I., Vogelzang N.J., Sridhar S.S. Examining the management of muscle-invasive bladder cancer by medical oncologists in the United States. Urol Oncol. 2014 Jul; 32 (5): 637–44. doi: 10.1016/j.urolonc.2013.12.012.Cowan N.G., Chen Y., Downs T.M., Bochner B.H., Apolo A.B., Porter M.P., La Rochelle J.C., Amling C.L., Koppie T.M. Neoadjuvant chemotherapy use in bladder cancer: a survey of current practice and opinions. Adv Urol. 2014; 2014: 746298. doi: 10.1155/2014/746298.Cowan N.G., Chen Y., Downs T.M., Bochner B.H., Apolo A.B., Porter M.P., La Rochelle J.C., Amling C.L., Koppie T.M. Neoadjuvant chemotherapy use in bladder cancer: a survey of current practice and opinions. Adv Urol. 2014; 2014: 746298. doi: 10.1155/2014/746298.El-Gehani F., North S., Ghosh S., Venner P. Improving the outcome of patients with muscle invasive urothelial carcinoma of the bladder with neoadjuvant gemcitabine/cisplatin chemotherapy: A single institution experience. Can Urol Assoc J. 2014 Mar; 8 (3–4): e287–93. doi: 10.5489/cuaj.1643.El-Gehani F., North S., Ghosh S., Venner P. Improving the outcome of patients with muscle invasive urothelial carcinoma of the bladder with neoadjuvant gemcitabine/cisplatin chemotherapy: A single institution experience. Can Urol Assoc J. 2014 Mar; 8 (3–4): e287–93. doi: 10.5489/cuaj.1643.Khaled H.M., Shafik H.E., Zabhloul M.S., Ghoneim M., Saber R.A., Manie M., Enein H.A., Megeed H.A., Mansur O., Sherbini M.E., Mahran T.Z., Kalawee M.E., Badran A., Ramadan S.M. Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy for Invasive Transitional and Squamous Cell Carcinoma of the Bladder: Effect on Survival and Bladder Preservation. Clin Genitourin Cancer. 2014 Oct; 12 (5): e233–40. doi: 10.1016/j.clgc.2014.04.002.Khaled H.M., Shafik H.E., Zabhloul M.S., Ghoneim M., Saber R.A., Manie M., Enein H.A., Megeed H.A., Mansur O., Sherbini M.E., Mahran T.Z., Kalawee M.E., Badran A., Ramadan S.M. Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy for Invasive Transitional and Squamous Cell Carcinoma of the Bladder: Effect on Survival and Bladder Preservation. Clin Genitourin Cancer. 2014 Oct; 12 (5): e233–40. doi: 10.1016/j.clgc.2014.04.002.von der Maase H., Hansen S., Roberts J.T., Dogliotti L., Oliver T., Moore M.J., Bodrogi I., Albers P., Knuth A., Lippert C.M., Kerbrat P., Sanchez Rovira P., Wersall P., Cleall S.P., Roychowdhury D.F., Tomlin I., Visseren-Grul C.M., Conte P.F. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000 Sep; 18 (17): 3068–77.von der Maase H., Hansen S., Roberts J.T., Dogliotti L., Oliver T., Moore M.J., Bodrogi I., Albers P., Knuth A., Lippert C.M., Kerbrat P., Sanchez Rovira P., Wersall P., Cleall S.P., Roychowdhury D.F., Tomlin I., Visseren-Grul C.M., Conte P.F. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000 Sep; 18 (17): 3068–77.Sakatani T., Shimizu Y., Sugino Y., Yamasaki T., Imamura M., Matsui Y., Inoue T., Okubo K., Kamba T., Yoshimura K., Ogawa O. Small cell carcinoma of the bladder. Hinyokika Kiyo. 2014 May; 60 (5): 221–5.Sakatani T., Shimizu Y., Sugino Y., Yamasaki T, Imamura M., Matsui Y., Inoue T., Okubo K., Kamba T., Yoshimura K., Ogawa O. Small cell carcinoma of the bladder. Hinyokika Kiyo. 2014 May; 60 (5): 221–5.Grossman H.B., Natale R.B., Tangen C.M., Speights V.O., Vogelzang N.J., Trump D.L., deVere White R.W., Sarosdy M.F., Wood D.P. Jr., Raghavan D., Crawford E.D. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003 Aug 28; 349 (9): 859–66.Grossman H.B., Natale R.B., Tangen C.M., Speights V.O., Vogelzang N.J., Trump D.L., deVere White R.W., Sarosdy M.F., Wood D.P. Jr., Raghavan D., Crawford E.D. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003 Aug 28; 349 (9): 859–66.Shelley M., Cleves A., Wilt T.J., Mason M. Gemcitabine for unresectable, locally advanced or metastatic bladder cancer. Cochrane Database Syst Rev. 2011 Apr 13; (4): CD008976. doi: 10.1002/14651858.CD008976.pub2.Shelley M., Cleves A., Wilt T.J., Mason M. Gemcitabine for unresectable, locally advanced or metastatic bladder cancer. Cochrane Database Syst Rev. 2011 Apr 13; (4): CD008976. doi: 10.1002/14651858. CD008976.pub2.

The authors declare that there are no conflicts of interest present.